Literature DB >> 34180027

Psoriatic arthritis in Africa.

Ajesh B Maharaj1, Adewale Adebajo2.   

Abstract

Psoriatic arthritis is a chronic immune-mediated inflammatory arthritis associated with the skin condition psoriasis. Although there is a large body of evidence regarding epidemiology, outcomes, and response to therapy from the Western world, there is a dearth of published literature from the African continent. There are many challenges responsible for this. Lack of resources, both human and financial, an enormous disease burden, and a focus on communicable diseases leave an unmet need for this important disease. This review explores and identifies these challenges and proposes ways to improve and overcome these deficiencies. We discuss the epidemiology of psoriatic arthritis in Africa, postulating the role of genetic and environmental factors, looking at the role of HLA-B 23, HLA-B 17, and HLA-B 8. Dietary intake as a contributing factor to the low prevalence of psoriatic arthritis and psoriasis is also discussed. Challenges on the African continent regarding limited access to specialised units/specialists, delay in diagnosis, limited attention by healthcare authorities to non-communicable diseases, and the difficulties in implementing international recommendations on the African continent are discussed. We also discuss a relative lack of data from the African continent, the cost of specialised medication in resource-poor countries, and comorbidities of psoriatic arthritis. The lack of validated questionnaires relevant to the African continent is also important and discussed. Finally, we discuss a proposed research agenda that will improve care, quality of life, and outcomes for patients with psoriatic arthritis on the African continent.
© 2021. International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Africa; Comorbidities; HIV; Psoriasis; Psoriatic arthritis

Year:  2021        PMID: 34180027     DOI: 10.1007/s10067-021-05841-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  71 in total

1.  Prevalence of psoriasis in Spain (Epiderma Project: phase I).

Authors:  C Ferrándiz; X Bordas; V García-Patos; S Puig; R Pujol; A Smandía
Journal:  J Eur Acad Dermatol Venereol       Date:  2001-01       Impact factor: 6.166

2.  Prevalence and treatment of psoriasis in the United Kingdom: a population-based study.

Authors:  Joel M Gelfand; Rachel Weinstein; Steven B Porter; Andrea L Neimann; Jesse A Berlin; David J Margolis
Journal:  Arch Dermatol       Date:  2005-12

Review 3.  Psoriatic arthritis.

Authors:  J M Moll; V Wright
Journal:  Semin Arthritis Rheum       Date:  1973       Impact factor: 5.532

4.  Skin diseases in Ghana and the UK.

Authors:  P T Doe; A Asiedu; J W Acheampong; C M Rowland Payne
Journal:  Int J Dermatol       Date:  2001-05       Impact factor: 2.736

5.  The prevalence of psoriasis in African Americans: results from a population-based study.

Authors:  Joel M Gelfand; Robert S Stern; Tamar Nijsten; Steven R Feldman; John Thomas; Joe Kist; Tara Rolstad; David J Margolis
Journal:  J Am Acad Dermatol       Date:  2005-01       Impact factor: 11.527

6.  Arthritis in psoriasis.

Authors:  L Green; O L Meyers; W Gordon; B Briggs
Journal:  Ann Rheum Dis       Date:  1981-08       Impact factor: 19.103

7.  The prevalence of psoriasis in Denmark.

Authors:  F Brandrup; A Green
Journal:  Acta Derm Venereol       Date:  1981       Impact factor: 4.437

8.  Psoriasis and psoriatic arthritis in African-American patients--the need to measure disease burden.

Authors:  Gail S Kerr; Seema Qaiyumi; John Richards; Hashem Vahabzadeh-Monshie; Chesahna Kindred; Sean Whelton; Florina Constantinescu
Journal:  Clin Rheumatol       Date:  2014-08-28       Impact factor: 2.980

9.  Dermatological disorders in Johannesburg, South Africa.

Authors:  S T Hartshorne
Journal:  Clin Exp Dermatol       Date:  2003-11       Impact factor: 3.470

10.  Prevalence of skin diseases in Ibadan, Nigeria.

Authors:  Adebola O Ogunbiyi; Olaniyi O M Daramola; Olatunji O Alese
Journal:  Int J Dermatol       Date:  2004-01       Impact factor: 2.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.